Novel purine-linked 1,2,3-triazole derivatives as effective anticancer agents: design, synthesis, docking, DFT, and...

The elaboration of a new family of purine molecules bearing triazole-acetamide units is presented. The structure assigned to such molecules was verified by various techniques, including FT-IR, NMR (¹H/¹³C), and HRMS analysis. The anticancer activity of the resulting compounds was evaluated in vitro against human lung cancer A549, cervical cancer HeLa, and colorectal cancer HCT116 cell lines. Some of the compounds were much more effective than the standard drug doxorubicin (DXN). Toxicity assessments using a healthy cell line indicated that most compounds displayed some level of toxicity, with only a few exceptions. Notably, compounds 5a, 5b, 5e, 5i, and 5j, unveiled significant cytotoxicity, resulting in notable inhibitory concentrations in cell survival against A549 (IC₅₀ = 4.02 - 15.34 µM), HeLa (6.02-22.12 µM), and HCT116 (6.11 - 22.57 µM) at a concentration of 10 µM. Based on the results, the synthesized compounds 5e, 5a, and 5d were able to inhibit A549 cell line by IC₅₀ of 4.02 ± 0.11, 5.20 ± 0.32, and 12.34 ± 0.25 µM, respectively. Additionally, the molecular docking approach was employed to correlate the in vitro anticancer inhibitory activity well with the in-silico study, and the result obtained corroborated that active analogues established several key interactions at positions Ala⁵⁶¹(A), Ile⁵⁵⁹(A), Gly³⁶⁷(A), Cys⁵¹³(A), Leu⁵⁵⁷(A), Arg⁴⁷⁰(A), Asn⁴⁶⁹(A), Thr⁵⁶⁰(A) with the active site of the lung cancer protein (PDB: 1 × 2 J). To further understand, the DFT studies have been explored. The results analysis revealed crucial information about the structure, electronic properties, and reactivity of these triazole scaffolds and identified the best inhibitor, 5e, in line with experimental observation. The experimental results were supported by molecular docking analysis, reinforcing the validity of the results. Extending our exploration, an analysis of the Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADME-Tox) profiling confirmed the safe use of these newly synthesized compounds, paving the way for promising applications in the medical field.